Scroll for more

news

Apr 27, 2018 articles

The challenges facing drug discovery

Ian Churcher, VP Drug Discovery, authors an article in The PharmaLetter this month looking at the challenges facing drug discovery. In it, Ian discusses the approaching disruption from technology companies and the shift the pharma must embrace to ensure that the industry can maintain its position as leaders in drug discovery.

Mar 15, 2018 announcements

BenevolentAI and group of UK charities partner to find a cure for blindness

BenevolentAI and Action Against AMD, a group of UK sight loss charities, have today announced their partnership to use BenevolentAI's technology to find treatments and a potential cure for the leading cause of blindness in the UK - 'age-related macular degeneration' (AMD).

Mar 5, 2018 articles

Could artificial intelligence cure ALS?

Dr Laura Ferraiuolo, Lecturer in Translational Neurobiology at SITraN in Sheffield and expert in ALS (Amyotrophic Lateral Sclerosis), disease talks about the advancement of research for ALS and the need for researchers to welcome new technologies to help them progress in finding potential new cures.

Mar 1, 2018 articles

Developing pharmaceuticals efficiently with artificial intelligence

Ken Mulvany talks to IBT about how the efficiency in the pharmaceutical industry can be increased by integrating AI methods.

Feb 27, 2018 articles

BenevolentAI's buy creates first AI firm capable of entire drug R&D

One of the largest AI enterprises in the world, BenevolentAI has acquired a research facility in Babraham,  FierceBiotech is reporting on it.

Feb 20, 2018 articles

Targeted protein degraders are redefining how small molecules look and act

Ian Churcher talks to chemical engineering news about targeted protein degradation.

Feb 13, 2018 articles

Digital Innovators: Q&A with BenevolentAI founder and chairman Ken Mulvany

Ken Mulvany talks to CityAm about AI, innovations and his ambitions for BenevolentAI

Feb 10, 2018 articles

BBC PODCASTS | The Shock of the New: Relationship between science, business and the consumer

Listen to Jackie Hunter taking part to the BBC podcast with Evan Davis to discuss the relationship between three important pillars of modern society: science, business and the consumer. Is the public right to be suspicious of business and the science it's selling? Why do some us fear GM foods, nanotechnology, AI and gene editing?

Oct 3, 2017 articles

How Close Are We to Curing ALS? A Review of Biotech’s Efforts

Read more about the current advancements and innovations made towards finding a cure for ALS (Lou Gehrig’s disease)

Aug 31, 2017 articles

This AI unicorn is disrupting the pharma industry in a big way

WIRED talks to Jackie Hunter about the positive disruption BenevolentAI is bringing to the pharma industry, and the scientific unknowns its helping to unlock using AI.

Aug 22, 2017 articles

BenevolentAI poaches drug discovery executive from GlaxoSmithKline

FierceBiotech covers the news that we have hired Dr Ian Churcher MA, DPhil as VP of Drug Discovery and Preclinical development. Ian joins from GSK where he previously headed up a Discovery Performance Unit.

Aug 22, 2017 announcements

BenevolentAI hires Head of GSK Discovery Performance Unit as VP Drug discovery

BenevolentAI, one of the world’s largest private AI companies, today announced it has hired Dr Ian Churcher as its new VP of Drug Discovery & Preclinical Development of its bioscience subsidiary BenevolentBio.

Jul 7, 2017 articles

Machine Learning and the march towards precision medicine

Taking a closer look at how big data and machine learning is transforming precision medicine, Adi Gaskell covers our work at BenevolentAI and the partnership with Sheffield Institute for Translational Neuroscience (SITraN) for Motor Neuron Disease research.

Jul 5, 2017 articles

Could AI help treat Motor Neurone Disease?

We teamed up with Sheffield Institute for Translational Neuroscience (SITraN) to test some of our AI-driven hypotheses in its ALS disease models. Dr Laura Ferraiulo, co-lead on the project from SITraN, spoke to IDG Connect about how this led to a potentially major breakthrough.

Jun 15, 2017 articles

BenevolentAI: drug research startup goes on hiring spree as UK’s artificial intelligence sector booms

Our founder Ken Mulvany features in an article looking at the UK’s growing performance in AI technology and the investment the country’s industry is attracting. Ken speaks to Bloomberg’s Giles Turner about BenevolentAI's hiring spree and the 50 roles we are looking to fill.

May 25, 2017 announcements

AI enabled research shows delay in onset of motor neurone disease

Sheffield and London, UK - 25 May 2017.  The Sheffield Institute for Translational Neuroscience (SITraN), part of the University of Sheffield and one of the world’s leading centres for research into Motor Neurone Disease, Alzheimer’s and Parkinson’s Disease, today announced that its research into a drug candidate discovered by British artificial intelligence firm BenevolentAI has delivered positive results.

Apr 26, 2017 articles

9 Computational Drug Discovery Startups Using AI

Nanalyze includes BenevolentAI in its round up of computational drug discovery start-ups using AI.

Apr 25, 2017 articles

A British tech unicorn is trying to cure Alzheimer's and ALS with artificial intelligence

Ken Mulvany, is interviewed by Business Insider UK in an article exploring BenevolentAI’s work to develop new drugs for diseases like Alzheimer’s and ALS.

Apr 13, 2017 articles

BenevolentAI to power small molecule drug discovery BenevolentAI to power small molecule drug discovery

This week, Pharmaphorum covered our partnership announcement with MRC Technology. We’ve teamed up with the independent research charity to investigate new small molecule and antibody drug candidates, combining our technology and R&D experience with their expertise.

Apr 11, 2017 announcements

BenevolentAI agrees partnership with medical research charity MRC technology

London, 11 April 2017 – BenevolentAI, a British artificial intelligence company, today announced that it has partnered with MRC Technology (“MRCT”), a medical research charity, to explore drug discovery initiatives in the field of small molecules and antibodies.

Mar 20, 2017 articles

BenevolentAI Q&A: Techworld meets Dr Jackie Hunter, CEO of BenevolentBio

An interview with Jackie Hunter, CEO BenevolentBio, the drug discovery arm of BenevolentAI

Mar 20, 2017 articles

Machines are Helping Healthcare: An Interview with their Biotech Leader

Jackie Hunter gives an interview to Labiotech around machine and healthcare and how AI could be the solution for a broken drug development process